PharmTech Drug Digest 11.20
News|Articles|June 18, 2015

SGS to Open New QC Lab Near Paris

A new SGS Life Science Services laboratory outside Paris is designed for bio/pharmaceutical quality control testing.

SGS Life Science Services has announced the June 29 opening of a new bio/pharmaceutical quality control laboratory at Villeneuve La Garenne, a Paris suburb. This multi-million Euro investment will serve the French market, support biologics development, and will operate under good manufacturing practices.

The new laboratory, which replaces an existing facility in Clichy, will incorporate infrastructure and equipment to meet the current and future demands of its bio/pharmaceutical clients, the company reports.

The 2100-square meter facility, located near the main logistics hubs, has been designed and built specifically for the needs of the pharmaceutical industry. Services currently available in Clichy will be transferred to Villeneuve La Garenne, with an emphasis on fume hoods to effectively treat organic products and classified carcinogenic, mutagenic, and reprotoxic substances.

In addition, SGS will introduce services to address the growing biopharmaceutical pipeline with capabilities for mycoplasma tests and amino acid analysis. The company has created a new mycoplasma detection department and hired Aude Sanchez, as project manager. Using fluorescence detection methods and automated DNA extraction combined with qPCR, the laboratory will be able to detect more than 90 species of mycoplasmas and achieve results in 48–72 hours, the company reports.

Source: SGS Life Science Services


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.